SL 01 is a prodrug of gemcitabine , the nucleoside analog used intravenously to treat various cancers that was designed for improved oral bioavailability. SL 01 can inhibit the growth of human non-small cell lung cancer NCI-H460 cells, colon cancer HCT-116 cells, and breast cancer MCF-7 cells (IC50s = 0.78, 0.92, and 0.64 μM, respectively), inducing apoptosis. In nude mice bearing NCI-H460, HCT-116, or MCF-7 cancer cell xenografts, SL 01 at 10-50 μM/kg has been shown to delay tumor growth.
1) Li et al. (2011), A cell-based high-throughput assay for the screening of small-molecule inhibitors of p53-MDM2 interaction; J. Biomol. Screening, 16 450
